Latest Pharmaceuticals News

Page 27 of 73
Clarity Pharmaceuticals has raised $203 million to accelerate its copper-64 and copper-67 radiopharmaceutical pipeline, targeting prostate and neuroendocrine cancers with multiple FDA Fast Track trials underway.
Ada Torres
Ada Torres
25 Nov 2025
Acrux Ltd reported a remarkable surge in licensing revenue from its topical generics portfolio alongside a strategic pivot towards innovative drug delivery R&D at its 2025 Annual General Meeting.
Ada Torres
Ada Torres
25 Nov 2025
Island Pharmaceuticals has secured membership in the Medical Countermeasures Coalition, positioning its antiviral Galidesivir for critical US government stockpiling and regulatory milestones.
Ada Torres
Ada Torres
24 Nov 2025
The Foreign Investment Review Board has formally objected to Cosette Pharmaceuticals’ proposed acquisition of Mayne Pharma, casting serious doubt on the deal’s future and prompting Mayne to explore alternative paths.
Victor Sage
Victor Sage
21 Nov 2025
Alterity Therapeutics announces significant board changes, including the retirement of founding chairman Geoffrey Kempler and appointment of CEO Dr David Stamler as Managing Director, aligning leadership with its Phase 3 clinical ambitions.
Ada Torres
Ada Torres
21 Nov 2025
Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a brief delay as FIRB extends its approval deadline, prompting a reschedule of the critical court hearing to November 23.
Ada Torres
Ada Torres
20 Nov 2025
Amplia Therapeutics has secured positive feedback from the US FDA on its Phase 2b/3 trial design for narmafotinib in pancreatic cancer, paving the way for a late 2026 trial start.
Ada Torres
Ada Torres
20 Nov 2025
Cann Group Limited has successfully raised an additional $2.5 million through a Share Purchase Plan and shortfall placement, complementing a prior $6.5 million institutional placement. These funds will primarily support debt repayment and strengthen the company’s financial position.
Ada Torres
Ada Torres
20 Nov 2025
Island Pharmaceuticals has engaged a top Washington DC government affairs firm to accelerate its US biodefence strategy, focusing on its antiviral drug Galidesivir amid promising FDA regulatory signals.
Ada Torres
Ada Torres
20 Nov 2025
AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.
Ada Torres
Ada Torres
20 Nov 2025
AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.
Victor Sage
Victor Sage
20 Nov 2025
AFT Pharmaceuticals has reported a robust first half of FY26, posting a 33% revenue increase to a record $114.9 million and returning to profitability amid strong growth in Australia and international markets. The company’s advancing R&D pipeline and strategic licensing deals position it well for ambitious FY27 targets.
Victor Sage
Victor Sage
20 Nov 2025